All In Biotech

Drug Trial Radar · NCT01358435

Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects

Randomized,Single Center,Double Blind,Two-period,Crossover Glucose Clamp Trial Study to Test Bioequivalence Between Two Recombinant Human Mixed Insulins-Wockhardt's Human/Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Dec 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

53

Actual

Start

Jan 2011

Primary completion

May 2011

Study completion May 2011

Sponsor

Lead sponsor
WockhardtIndustry
Sponsor type
Industry
First posted
May 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Health services research
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this trial is to demonstrate bioequivalence of Wosulin 70/30 to Novolin® 70/30 with regard to its total and to its maximum serum insulin concentrations.

Conditions

  • Diabetes Mellitus

Interventions

  • 30% Regular Insulin Human Neutral and 70%Isophane InsulinBiological

    Total Dose per subject is 0.4 IU/Kg given subcutaneously.

  • Novolin 70/30Biological

    Total Dose per subject is 0.4IU/Kg given Subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean AUC0-24h and CmaxTime frame: Visit 2 and 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Profil Institute for Clinical Research

    Chula Vista, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.